Biomarker-driven therapies for triple-negative breast cancer

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody.

Year of Production:
Running Time:
Color/Sound:

2015
02:38
Color/Sound

Comments are closed.